Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Дифференцированный подход к диагностике и терапии деменции
Дифференцированный подход к диагностике и терапии деменции
Васенина Е.Е., Левин О.С. Дифференцированный подход к диагностике и терапии деменции. Consilium Medicum. Неврология и Ревматология (Прил.). 2016; 2: 71–75.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Распространенность деменции и, в частности, болезни Альцгеймера с каждым годом увеличивается в связи с тенденцией к постарению населения. Топические особенности повреждения при разных формах деменции обусловливают особенности поведения, клинической картины болезни и нейропсихологического профиля больных при тестировании. Дифференцированный подход к диагностике деменции определяет правильную тактику лечения таких пациентов.
Ключевые слова: деменция, болезнь Альцгеймера, лечение, мемантин.
Key words: dementia, Alzheimer disease, treatment, memantine.
Ключевые слова: деменция, болезнь Альцгеймера, лечение, мемантин.
________________________________________________
Key words: dementia, Alzheimer disease, treatment, memantine.
Полный текст
Список литературы
1. Левин О.С., Васенина Е.Е. Диагностика и лечение когнитивных нарушений и деменции. М.: Медпресс-информ, 2015. / Levin O.S., Vasenina E.E. Diagnostika i lechenie kognitivnykh narushenii i dementsii. M.: Medpress-inform, 2015. [in Russian]
2. Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff (Millwood) 2014; 33 (4): 658–66.
3. Alzheimer’s Disease International. World Alzheimer report 2013. www.alz.co.uk/research/world-report-2013
4. Гаврилова С.И. Болезнь Альцгеймера. Современные представления о диагностике и терапии. М.: Москва, 2012. / Gavrilova S.I. Bolezn' Al'tsgeimera. Sovremennye predstavleniia o diagnostike i terapii. M.: Moskva, 2012. [in Russian]
5. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. М.: МЕДпресс-информ, 2011. / Iakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii. M.: MEDpress-inform, 2011. [in Russian]
6. Васенина Е.Е., Левин О.С. Особенности клинической картины и лечения умеренной и тяжелой болезни Альцгеймера. Журн. неврологии и психиатрии им. C.C.Корсакова. 2015; 115 (6–2): 17–25. / Vasenina E.E., Levin O.S. Osobennosti klinicheskoi kartiny i lecheniia umerennoi i tiazheloi bolezni Al'tsgeimera. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (6–2): 17–25. [in Russian]
7. Левин О.С. Алгоритмы диагностики и лечения деменции. М.: Медпресс-информ, 2011. / Levin O.S. Algoritmy diagnostiki i lecheniia dementsii. M.: Medpress-inform, 2011. [in Russian]
8. Nasreddine Z, Phillips N, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc 2005; 53 (4): 695–9. DOI: 10.1111/j.1532-5415.2005.53221.x
9. Burns A, Brayne C, Folstein M. Key Papers in Geriatric Psychiatry: mini mental state: a practical method for grading the cognitive state of patients for the clinician. M.Folstein, S.Folstein, P.McHugh. J Psychiatric Res 1975; 12: 189–98. Int J Geriatr Psychiatry 1998; 13 (5): 285–94. DOI: 10.1002/(sici)1099-1166(199805)13:5<285::aid-gps753>3.3.co;2-m
10. Гуторова Д.А., Васенина Е.Е., Левин О.С. Скрининг когнитивных нарушений у лиц пожилого и старческого возраста с помощью шкалы 3-КТ. Журн. неврологии и психиатрии им. С.С.Корсакова. Спецвып. 2016; 116 (6): 35–40. / Gutorova D.A., Vasenina E.E., Levin O.S. Skrining kognitivnykh narushenii u lits pozhilogo i starcheskogo vozrasta s pomoshch'iu shkaly 3-KT. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. Spetsvyp. 2016; 116 (6): 35–40. [in Russian]
11. Аникина М.А., Васенина Е.Е., Левин О.С. Мемантин в терапии деменции. Consilium Medicum. 2013; 15 (2): 95–100. / Anikina M.A., Vasenina E.E., Levin O.S. Memantin v terapii dementsii. Consilium Medicum. 2013; 15 (2): 95–100. [in Russian]
12. Боголепова А.Н. Проблемы медикаментозной терапии больных с когнитивными нарушениями. Consilium Medicum. 2012; 14 (2): 18–22. / Bogolepova A.N. Problemy medikamentoznoi terapii bol'nykh s kognitivnymi narusheniiami. Consilium Medicum. 2012; 14 (2): 18–22. [in Russian]
13. Winblad B, Jones R, Wirth Y et al. Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials. Dement Geriatr Cognitive Disord 2007; 24 (1): 20–7.
14. Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 2011; 27 (8): 769–76.
15. Gauthier S, Wirth Y, Möbius H. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised , controlled studies. Int J Geriatr Psychiatry 2005; 20 (5): 459–64.
16. McShane R, Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; Issue 2: CD003154.
17. Förstl H, Stamouli SS, Janetzky W et al. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord 2011; 32 (4): 267–72.
18. Roe CM, Anderson MJ, Spivack B. Use of Anticholinergic Medications by Older Adults with Dementia. J Am Geriatr Soc 2002; 50: 836–42. DOI: 10.1046/j.1532-5415.2002.50208
19. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 60: 616–31. DOI:10.1111/j.1532-5415.2012.03923.
20. US Food and Drug Administration. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration; 2005. http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdf.
21. Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer’s disease studies: What can we learn? Alzheimers Dement 2014; Mar 6. pii: S1552-5260(13)02944-0.
22. McKhann G, Knopman D, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia 2011; 7 (3): 263–9.
2. Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff (Millwood) 2014; 33 (4): 658–66.
3. Alzheimer’s Disease International. World Alzheimer report 2013. www.alz.co.uk/research/world-report-2013
4. Gavrilova S.I. Bolezn' Al'tsgeimera. Sovremennye predstavleniia o diagnostike i terapii. M.: Moskva, 2012. [in Russian]
5. Iakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii. M.: MEDpress-inform, 2011. [in Russian]
6. Vasenina E.E., Levin O.S. Osobennosti klinicheskoi kartiny i lecheniia umerennoi i tiazheloi bolezni Al'tsgeimera. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (6–2): 17–25. [in Russian]
7. Levin O.S. Algoritmy diagnostiki i lecheniia dementsii. M.: Medpress-inform, 2011. [in Russian]
8. Nasreddine Z, Phillips N, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc 2005; 53 (4): 695–9. DOI: 10.1111/j.1532-5415.2005.53221.x
9. Burns A, Brayne C, Folstein M. Key Papers in Geriatric Psychiatry: mini mental state: a practical method for grading the cognitive state of patients for the clinician. M.Folstein, S.Folstein, P.McHugh. J Psychiatric Res 1975; 12: 189–98. Int J Geriatr Psychiatry 1998; 13 (5): 285–94. DOI: 10.1002/(sici)1099-1166(199805)13:5<285::aid-gps753>3.3.co;2-m
10. Gutorova D.A., Vasenina E.E., Levin O.S. Skrining kognitivnykh narushenii u lits pozhilogo i starcheskogo vozrasta s pomoshch'iu shkaly 3-KT. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. Spetsvyp. 2016; 116 (6): 35–40. [in Russian]
11. Anikina M.A., Vasenina E.E., Levin O.S. Memantin v terapii dementsii. Consilium Medicum. 2013; 15 (2): 95–100. [in Russian]
12. Bogolepova A.N. Problemy medikamentoznoi terapii bol'nykh s kognitivnymi narusheniiami. Consilium Medicum. 2012; 14 (2): 18–22. [in Russian]
13. Winblad B, Jones R, Wirth Y et al. Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials. Dement Geriatr Cognitive Disord 2007; 24 (1): 20–7.
14. Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 2011; 27 (8): 769–76.
15. Gauthier S, Wirth Y, Möbius H. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised , controlled studies. Int J Geriatr Psychiatry 2005; 20 (5): 459–64.
16. McShane R, Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; Issue 2: CD003154.
17. Förstl H, Stamouli SS, Janetzky W et al. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord 2011; 32 (4): 267–72.
18. Roe CM, Anderson MJ, Spivack B. Use of Anticholinergic Medications by Older Adults with Dementia. J Am Geriatr Soc 2002; 50: 836–42. DOI: 10.1046/j.1532-5415.2002.50208
19. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 60: 616–31. DOI:10.1111/j.1532-5415.2012.03923.
20. US Food and Drug Administration. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration; 2005. http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdf.
21. Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer’s disease studies: What can we learn? Alzheimers Dement 2014; Mar 6. pii: S1552-5260(13)02944-0.
22. McKhann G, Knopman D, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia 2011; 7 (3): 263–9.
2. Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff (Millwood) 2014; 33 (4): 658–66.
3. Alzheimer’s Disease International. World Alzheimer report 2013. www.alz.co.uk/research/world-report-2013
4. Гаврилова С.И. Болезнь Альцгеймера. Современные представления о диагностике и терапии. М.: Москва, 2012. / Gavrilova S.I. Bolezn' Al'tsgeimera. Sovremennye predstavleniia o diagnostike i terapii. M.: Moskva, 2012. [in Russian]
5. Яхно Н.Н., Захаров В.В., Локшина А.Б. и др. Деменции. М.: МЕДпресс-информ, 2011. / Iakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii. M.: MEDpress-inform, 2011. [in Russian]
6. Васенина Е.Е., Левин О.С. Особенности клинической картины и лечения умеренной и тяжелой болезни Альцгеймера. Журн. неврологии и психиатрии им. C.C.Корсакова. 2015; 115 (6–2): 17–25. / Vasenina E.E., Levin O.S. Osobennosti klinicheskoi kartiny i lecheniia umerennoi i tiazheloi bolezni Al'tsgeimera. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (6–2): 17–25. [in Russian]
7. Левин О.С. Алгоритмы диагностики и лечения деменции. М.: Медпресс-информ, 2011. / Levin O.S. Algoritmy diagnostiki i lecheniia dementsii. M.: Medpress-inform, 2011. [in Russian]
8. Nasreddine Z, Phillips N, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc 2005; 53 (4): 695–9. DOI: 10.1111/j.1532-5415.2005.53221.x
9. Burns A, Brayne C, Folstein M. Key Papers in Geriatric Psychiatry: mini mental state: a practical method for grading the cognitive state of patients for the clinician. M.Folstein, S.Folstein, P.McHugh. J Psychiatric Res 1975; 12: 189–98. Int J Geriatr Psychiatry 1998; 13 (5): 285–94. DOI: 10.1002/(sici)1099-1166(199805)13:5<285::aid-gps753>3.3.co;2-m
10. Гуторова Д.А., Васенина Е.Е., Левин О.С. Скрининг когнитивных нарушений у лиц пожилого и старческого возраста с помощью шкалы 3-КТ. Журн. неврологии и психиатрии им. С.С.Корсакова. Спецвып. 2016; 116 (6): 35–40. / Gutorova D.A., Vasenina E.E., Levin O.S. Skrining kognitivnykh narushenii u lits pozhilogo i starcheskogo vozrasta s pomoshch'iu shkaly 3-KT. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. Spetsvyp. 2016; 116 (6): 35–40. [in Russian]
11. Аникина М.А., Васенина Е.Е., Левин О.С. Мемантин в терапии деменции. Consilium Medicum. 2013; 15 (2): 95–100. / Anikina M.A., Vasenina E.E., Levin O.S. Memantin v terapii dementsii. Consilium Medicum. 2013; 15 (2): 95–100. [in Russian]
12. Боголепова А.Н. Проблемы медикаментозной терапии больных с когнитивными нарушениями. Consilium Medicum. 2012; 14 (2): 18–22. / Bogolepova A.N. Problemy medikamentoznoi terapii bol'nykh s kognitivnymi narusheniiami. Consilium Medicum. 2012; 14 (2): 18–22. [in Russian]
13. Winblad B, Jones R, Wirth Y et al. Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials. Dement Geriatr Cognitive Disord 2007; 24 (1): 20–7.
14. Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 2011; 27 (8): 769–76.
15. Gauthier S, Wirth Y, Möbius H. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised , controlled studies. Int J Geriatr Psychiatry 2005; 20 (5): 459–64.
16. McShane R, Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; Issue 2: CD003154.
17. Förstl H, Stamouli SS, Janetzky W et al. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord 2011; 32 (4): 267–72.
18. Roe CM, Anderson MJ, Spivack B. Use of Anticholinergic Medications by Older Adults with Dementia. J Am Geriatr Soc 2002; 50: 836–42. DOI: 10.1046/j.1532-5415.2002.50208
19. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 60: 616–31. DOI:10.1111/j.1532-5415.2012.03923.
20. US Food and Drug Administration. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration; 2005. http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdf.
21. Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer’s disease studies: What can we learn? Alzheimers Dement 2014; Mar 6. pii: S1552-5260(13)02944-0.
22. McKhann G, Knopman D, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia 2011; 7 (3): 263–9.
________________________________________________
2. Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff (Millwood) 2014; 33 (4): 658–66.
3. Alzheimer’s Disease International. World Alzheimer report 2013. www.alz.co.uk/research/world-report-2013
4. Gavrilova S.I. Bolezn' Al'tsgeimera. Sovremennye predstavleniia o diagnostike i terapii. M.: Moskva, 2012. [in Russian]
5. Iakhno N.N., Zakharov V.V., Lokshina A.B. i dr. Dementsii. M.: MEDpress-inform, 2011. [in Russian]
6. Vasenina E.E., Levin O.S. Osobennosti klinicheskoi kartiny i lecheniia umerennoi i tiazheloi bolezni Al'tsgeimera. Zhurn. nevrologii i psikhiatrii im. C.C.Korsakova. 2015; 115 (6–2): 17–25. [in Russian]
7. Levin O.S. Algoritmy diagnostiki i lecheniia dementsii. M.: Medpress-inform, 2011. [in Russian]
8. Nasreddine Z, Phillips N, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc 2005; 53 (4): 695–9. DOI: 10.1111/j.1532-5415.2005.53221.x
9. Burns A, Brayne C, Folstein M. Key Papers in Geriatric Psychiatry: mini mental state: a practical method for grading the cognitive state of patients for the clinician. M.Folstein, S.Folstein, P.McHugh. J Psychiatric Res 1975; 12: 189–98. Int J Geriatr Psychiatry 1998; 13 (5): 285–94. DOI: 10.1002/(sici)1099-1166(199805)13:5<285::aid-gps753>3.3.co;2-m
10. Gutorova D.A., Vasenina E.E., Levin O.S. Skrining kognitivnykh narushenii u lits pozhilogo i starcheskogo vozrasta s pomoshch'iu shkaly 3-KT. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. Spetsvyp. 2016; 116 (6): 35–40. [in Russian]
11. Anikina M.A., Vasenina E.E., Levin O.S. Memantin v terapii dementsii. Consilium Medicum. 2013; 15 (2): 95–100. [in Russian]
12. Bogolepova A.N. Problemy medikamentoznoi terapii bol'nykh s kognitivnymi narusheniiami. Consilium Medicum. 2012; 14 (2): 18–22. [in Russian]
13. Winblad B, Jones R, Wirth Y et al. Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials. Dement Geriatr Cognitive Disord 2007; 24 (1): 20–7.
14. Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer's disease. Int J Geriatr Psychiatry 2011; 27 (8): 769–76.
15. Gauthier S, Wirth Y, Möbius H. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised , controlled studies. Int J Geriatr Psychiatry 2005; 20 (5): 459–64.
16. McShane R, Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; Issue 2: CD003154.
17. Förstl H, Stamouli SS, Janetzky W et al. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord 2011; 32 (4): 267–72.
18. Roe CM, Anderson MJ, Spivack B. Use of Anticholinergic Medications by Older Adults with Dementia. J Am Geriatr Soc 2002; 50: 836–42. DOI: 10.1046/j.1532-5415.2002.50208
19. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2012; 60: 616–31. DOI:10.1111/j.1532-5415.2012.03923.
20. US Food and Drug Administration. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. US Food and Drug Administration; 2005. http://www.cchrint.org/pdfs/US_Food_and_Drug_Administration_Warnings_on_Antipsychotic_Drugs.pdf.
21. Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer’s disease studies: What can we learn? Alzheimers Dement 2014; Mar 6. pii: S1552-5260(13)02944-0.
22. McKhann G, Knopman D, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dementia 2011; 7 (3): 263–9.
Авторы
Е.Е.Васенина*, О.С.Левин
ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*hel_vas@mail.ru
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*hel_vas@mail.ru
ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России. 125993, Россия, Москва, ул. Баррикадная, д. 2/1
*hel_vas@mail.ru
________________________________________________
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation. 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
*hel_vas@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.